Develops antibody drug candidates for patients with autoimmune and inflammatory diseases, including hidradenitis suppurativa and systemic sclerosis.
10-K for FY2025, filed Mar 19, 2026We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory…View ↗
We have in-licensed three clinical-stage product candidates:View ↗
We are currently conducting two global Phase 2 clinical trials evaluating tibulizumab in adult participants, each of which includes an…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 19, 2026
8-K, filed Nov 9, 2026
Study did not meet primary endpoint of percentage change from baseline in total abscess and inflammatory nodule (AN) count at Week 16View ↗
From no operations to drug development The older report describes a company with no operations formed to combine with another business; the latest describes a biotechnology company developing medicines for autoimmune and inflammatory diseases.
Loading...